189 related articles for article (PubMed ID: 32814172)
1. The disruption of protein-protein interactions as a therapeutic strategy for prostate cancer.
Matos B; Howl J; Jerónimo C; Fardilha M
Pharmacol Res; 2020 Nov; 161():105145. PubMed ID: 32814172
[TBL] [Abstract][Full Text] [Related]
2. Recent progress in the development of protein-protein interaction inhibitors targeting androgen receptor-coactivator binding in prostate cancer.
Biron E; Bédard F
J Steroid Biochem Mol Biol; 2016 Jul; 161():36-44. PubMed ID: 26196120
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer: the need for biomarkers and new therapeutic targets.
Felgueiras J; Silva JV; Fardilha M
J Zhejiang Univ Sci B; 2014 Jan; 15(1):16-42. PubMed ID: 24390742
[TBL] [Abstract][Full Text] [Related]
4. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
5. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
[TBL] [Abstract][Full Text] [Related]
6. Targeting prostate cancer cells with enzalutamide-HDAC inhibitor hybrid drug 2-75.
Hu WY; Xu L; Chen B; Ou S; Muzzarelli KM; Hu DP; Li Y; Yang Z; Vander Griend DJ; Prins GS; Qin Z
Prostate; 2019 Jul; 79(10):1166-1179. PubMed ID: 31135075
[TBL] [Abstract][Full Text] [Related]
7. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
[TBL] [Abstract][Full Text] [Related]
8. Exploring Proteomic Drug Targets, Therapeutic Strategies and Protein - Protein Interactions in Cancer: Mechanistic View.
Dar KB; Bhat AH; Amin S; Anjum S; Reshi BA; Zargar MA; Masood A; Ganie SA
Curr Cancer Drug Targets; 2019; 19(6):430-448. PubMed ID: 30073927
[TBL] [Abstract][Full Text] [Related]
9. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
[TBL] [Abstract][Full Text] [Related]
10. New therapies for castration-resistant prostate cancer: efficacy and safety.
Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
[TBL] [Abstract][Full Text] [Related]
11. Insights into Chemoresistance of Prostate Cancer.
Zhang W; Meng Y; Liu N; Wen XF; Yang T
Int J Biol Sci; 2015; 11(10):1160-70. PubMed ID: 26327810
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of Anti-Cancer Activity of Curcumin on Androgen-Dependent and Androgen-Independent Prostate Cancer.
Abd Wahab NA; Lajis NH; Abas F; Othman I; Naidu R
Nutrients; 2020 Mar; 12(3):. PubMed ID: 32131560
[TBL] [Abstract][Full Text] [Related]
13. Extracellular Vesicle-Mediated Reversal of Paclitaxel Resistance in Prostate Cancer.
Wang JQ; DeChalus A; Chatterjee DN; Keller ET; Mizokami A; Camussi G; Mendelsohn AR; Renzulli Ii JF; Quesenberry PJ; Chatterjee D
Crit Rev Oncog; 2015; 20(5-6):407-17. PubMed ID: 27279238
[TBL] [Abstract][Full Text] [Related]
14. BAG1L: a promising therapeutic target for androgen receptor-dependent prostate cancer.
Lee II; Kuznik NC; Rottenberg JT; Brown M; Cato ACB
J Mol Endocrinol; 2019 May; 62(4):R289-R299. PubMed ID: 30913537
[TBL] [Abstract][Full Text] [Related]
15. Novel drugs targeting the androgen receptor pathway in prostate cancer.
Mateo J; Smith A; Ong M; de Bono JS
Cancer Metastasis Rev; 2014 Sep; 33(2-3):567-79. PubMed ID: 24390422
[TBL] [Abstract][Full Text] [Related]
16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
17. New approaches to targeting the androgen receptor pathway in prostate cancer.
Velho PI; Bastos DA; Antonarakis ES
Clin Adv Hematol Oncol; 2021 Apr; 19(4):228-240. PubMed ID: 33989272
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
Chen X; Liu J; Cheng L; Li C; Zhang Z; Bai Y; Wang R; Han T; Huang C; Kong Y; Feng F; Liu X
Prostate; 2020 Feb; 80(3):256-266. PubMed ID: 31856338
[TBL] [Abstract][Full Text] [Related]
19. Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.
Lakshmana G; Baniahmad A
Int J Cancer; 2019 Apr; 144(8):1775-1779. PubMed ID: 30125354
[TBL] [Abstract][Full Text] [Related]
20. PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy.
Zeng J; Liu W; Fan YZ; He DL; Li L
Theranostics; 2018; 8(1):109-123. PubMed ID: 29290796
[No Abstract] [Full Text] [Related]
[Next] [New Search]
